LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02652871 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: LY2510924
DRUG: Idarubicin
DRUG: Cytarabine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]